City of Hope is a nonprofit academic medical center and biomedical research organization headquartered in Duarte, California. It is an NCI-designated comprehensive cancer center with a nationwide care network and an affiliated research enterprise (including the Beckman Research Institute). Founded in 1913, the institution focuses on advancing prevention, diagnosis, and treatment of cancer and related diseases.
City of Hope conducts basic, translational, and clinical research across oncology, immunology, and metabolic disorders. It develops biologics, small-molecule therapeutics, and cell and gene therapies, and operates GMP facilities for clinical-grade manufacturing (such as viral vectors and cellular therapies). The organization is known for leadership in hematologic malignancies and bone marrow/stem cell transplantation, and it sponsors and participates in multicenter clinical trials. City of Hope collaborates with industry through technology transfer, licensing, and research partnerships to move laboratory discoveries into clinical practice.
None yet. When a new project in the record names City of Hope as owner, partner or investor, it shows here.
FDA approves RYBREVANT FASPRO™ for EGFR-mutated NSCLC, offering faster, subcutaneous administration with fewer side effects compared to IV delivery.
